This study will assess naltrexone's effectiveness in treating alcoholism in women and provide
information on its potential value in treating eating disorders common among alcoholic women.
Alcoholic women with and without both eating disorders and depression will be randomly
assigned to placebo or naltrexone treatment. Each group will receive behavioral therapy for
12 weeks, with followup 6 months after treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)